Tags

Type your tag names separated by a space and hit enter

Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial.
Pediatrics 2010; 126(3):e526-33Ped

Abstract

OBJECTIVE

To test the efficacy of Lactobacillus reuteri on infantile colic and to evaluate its relationship to the gut microbiota.

STUDY DESIGN

Fifty exclusively breastfed colicky infants, diagnosed according to modified Wessel's criteria, were randomly assigned to receive either L reuteri DSM 17 938 (10(8) colony-forming units) or placebo daily for 21 days. Parental questionnaires monitored daily crying time and adverse effects. Stool samples were collected for microbiologic analysis.

RESULTS

Forty-six infants (L reuteri group: 25; placebo group: 21) completed the trial. Daily crying times in minutes/day (median [interquartile range]) were 370 (120) vs 300 (150) (P=.127) on day 0 and 35.0 (85) vs 90.0 (148) (P=.022) on day 21, in the L reuteri and placebo groups, respectively. Responders (50% reduction in crying time from baseline) were significantly higher in the L reuteri group versus placebo group on days 7 (20 vs 8; P=.006), 14 (24 vs 13; P=.007), and 21 (24 vs 15; P=.036). During the study, there was a significant increase in fecal lactobacilli (P=.002) and a reduction in fecal Escherichia coli and ammonia in the L reuteri group only (P=.001). There were no differences in weight gain, stooling frequency, or incidence of constipation or regurgitation between groups, and no adverse events related to the supplementation were observed.

CONCLUSION

L. reuteri DSM 17 938 at a dose of 10(8) colony-forming units per day in early breastfed infants improved symptoms of infantile colic and was well tolerated and safe. Gut microbiota changes induced by the probiotic could be involved in the observed clinical improvement.

Authors+Show Affiliations

Department of Pediatrics, Regina Margherita Children Hospital, University of Turin, Piazza Polonia, 94 10126 Turin, Italy. francesco.savino@unito.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20713478

Citation

Savino, Francesco, et al. "Lactobacillus Reuteri DSM 17938 in Infantile Colic: a Randomized, Double-blind, Placebo-controlled Trial." Pediatrics, vol. 126, no. 3, 2010, pp. e526-33.
Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010;126(3):e526-33.
Savino, F., Cordisco, L., Tarasco, V., Palumeri, E., Calabrese, R., Oggero, R., ... Matteuzzi, D. (2010). Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics, 126(3), pp. e526-33. doi:10.1542/peds.2010-0433.
Savino F, et al. Lactobacillus Reuteri DSM 17938 in Infantile Colic: a Randomized, Double-blind, Placebo-controlled Trial. Pediatrics. 2010;126(3):e526-33. PubMed PMID: 20713478.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. AU - Savino,Francesco, AU - Cordisco,Lisa, AU - Tarasco,Valentina, AU - Palumeri,Elisabetta, AU - Calabrese,Roberto, AU - Oggero,Roberto, AU - Roos,Stefan, AU - Matteuzzi,Diego, Y1 - 2010/08/16/ PY - 2010/8/18/entrez PY - 2010/8/18/pubmed PY - 2010/10/5/medline SP - e526 EP - 33 JF - Pediatrics JO - Pediatrics VL - 126 IS - 3 N2 - OBJECTIVE: To test the efficacy of Lactobacillus reuteri on infantile colic and to evaluate its relationship to the gut microbiota. STUDY DESIGN: Fifty exclusively breastfed colicky infants, diagnosed according to modified Wessel's criteria, were randomly assigned to receive either L reuteri DSM 17 938 (10(8) colony-forming units) or placebo daily for 21 days. Parental questionnaires monitored daily crying time and adverse effects. Stool samples were collected for microbiologic analysis. RESULTS: Forty-six infants (L reuteri group: 25; placebo group: 21) completed the trial. Daily crying times in minutes/day (median [interquartile range]) were 370 (120) vs 300 (150) (P=.127) on day 0 and 35.0 (85) vs 90.0 (148) (P=.022) on day 21, in the L reuteri and placebo groups, respectively. Responders (50% reduction in crying time from baseline) were significantly higher in the L reuteri group versus placebo group on days 7 (20 vs 8; P=.006), 14 (24 vs 13; P=.007), and 21 (24 vs 15; P=.036). During the study, there was a significant increase in fecal lactobacilli (P=.002) and a reduction in fecal Escherichia coli and ammonia in the L reuteri group only (P=.001). There were no differences in weight gain, stooling frequency, or incidence of constipation or regurgitation between groups, and no adverse events related to the supplementation were observed. CONCLUSION: L. reuteri DSM 17 938 at a dose of 10(8) colony-forming units per day in early breastfed infants improved symptoms of infantile colic and was well tolerated and safe. Gut microbiota changes induced by the probiotic could be involved in the observed clinical improvement. SN - 1098-4275 UR - https://www.unboundmedicine.com/medline/citation/20713478/Lactobacillus_reuteri_DSM_17938_in_infantile_colic:_a_randomized_double_blind_placebo_controlled_trial_ L2 - http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=20713478 DB - PRIME DP - Unbound Medicine ER -